MINERVA
NEUROSCIENCES, INC.

Annual Shareholders Meeting Company Presentation

Friday, 19th June 2020

MINERVA
NEUROSCIENCES, INC.

Forward-Looking Statement Safe-Harbor

This press release contains forward-looking statements which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts, reflect management's expectations as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the timing and scope of future clinical trials and results of clinical trials with roluperidone (MIN-101); the clinical and therapeutic potential of this compound; the timing and outcomes of future interactions with U.S. and foreign regulatory bodies; our ability to successfully develop and commercialize our therapeutic products; the sufficiency of our current cash position to fund our operations; and management's ability to successfully achieve its goals. These forward-looking statements are based on our current expectations and may differ materially from actual results due to a variety of factors including, without limitation, whether roluperidone will advance further in the clinical trials process and whether and when, if at all, it will receive final approval from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies and for which indications; whether any of our therapeutic products will be successfully marketed if approved; whether any of our therapeutic product discovery and development efforts will be successful; management's ability to successfully achieve its goals; our ability to raise additional capital to fund our operations on terms acceptable to us; and general economic conditions. These and other potential risks and uncertainties that could cause actual results to differ from the results predicted are more fully detailed under the caption "Risk Factors" in our filings with the Securities and Exchange Commission, including our Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, filed with the Securities and Exchange Commission on May 4, 2020. Copies of reports filed with the SEC are posted on our website at www.minervaneurosciences.com. The forward-looking statements in this press release are based on information available to us as of the date hereof, and we disclaim any obligation to update any forward-looking statements, except as required by law.

MINERVA NEUROSCIENCES, INC.

The last 12 months in view - 3 clinical programs in areas of high unmet medical need

Roluperidone: Negative Symptoms in Schizophrenia (Phase 3)

"Our goal is to treat negative symptoms: the most important drivers of everyday disability and a critical unmet medical need for patients with schizophrenia."

Dr Remy Luthringer, Executive Chairman & CEO

- Phase III study completed in a difficult environment
- Study did not meet primary endpoint in PANSS negative symptoms score
- Study showed significant functional improvement in patients (PSP)
- Roluperidone's efficacy in the Phase 3 successfully replicated the Phase 2b data
- Data under review by the Minerva team and its advisors
- Meeting with the FDA on path forward following completion of data review

MINERVA NEUROSCIENCES, INC.

Phase 3 : Efficacy - Primary Endpoint - Marder Negative Symptoms Factor Score (NSFS)



MINERVA NEUROSCIENCES, INC.

Phase 3 : Efficacy - Key Secondary Endpoint - Personal and Social Performance (PSP) Total Score



MINERVA NEUROSCIENCES, INC.

Comparison– Marder Negative Symptoms Factor Score (NSFS): Phase 2b versus Phase 3

Phase 2b NSFS



Phase 3 NSFS



Factor	MIN-101C03	MIN-101C07
Age at Baseline (yrs)	40	41
PANSS NS Subscore	27	27
PANSS Total Score	80	79
Placebo delta in PANSS NSFS (primary)	1.6	3.5
64 mg delta in PANSS NSFS (primary)	3.9	4.3

MINERVA NEUROSCIENCES, INC.

Minerva: Looking forward

Roluperidone: Negative Symptoms in Schizophrenia (Phase 3)

- Data under review by the Minerva team and its advisors
- Meeting with the FDA on path forward following completion of data review

Seltorexant: Insomnia and MDD (Phase 3)

- Three Phase IIb studies completed in 2019
- Phase III program design in process

MIN-117: MDD in patients with anxiety

- Phase 2b did not meet primary endpoint in late 2019
- High responding sub-groups of patients identified and under review

MINERVA
NEUROSCIENCES, INC.